PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

Weiss J, Kaczmar J, Chintakuntlawar A, Worden FP, Mehra R, Kang H, Zinner RG, Arnold SM, Bhateja P, Harrington K, Gupta S, Zhao Y, Pham DC, Najeeb S, Kaur V, Sukari A, Giri A, Panella TJ, Grewal J, Galligan B, Nadler E, Grant C, Arteta-Bulos R, Noble DJ, Schaaf D, Price KAR

Open source

DOI: 10.1001/jamaoncol.2026.3492
Published: 2026 Sep 17
Container: JAMA oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2026.3492,
  title = {PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.},
  author = {Weiss J and Kaczmar J and Chintakuntlawar A and Worden FP and Mehra R and Kang H and Zinner RG and Arnold SM and Bhateja P and Harrington K and Gupta S and Zhao Y and Pham DC and Najeeb S and Kaur V and Sukari A and Giri A and Panella TJ and Grewal J and Galligan B and Nadler E and Grant C and Arteta-Bulos R and Noble DJ and Schaaf D and Price KAR},
  year = {2026},
  journal = {JAMA oncology},
  doi = {10.1001/jamaoncol.2026.3492},
  url = {https://doi.org/10.1001/jamaoncol.2026.3492}
}

RIS

TY  - JOUR
TI  - PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
AU  - Weiss J
AU  - Kaczmar J
AU  - Chintakuntlawar A
AU  - Worden FP
AU  - Mehra R
AU  - Kang H
AU  - Zinner RG
AU  - Arnold SM
AU  - Bhateja P
AU  - Harrington K
AU  - Gupta S
AU  - Zhao Y
AU  - Pham DC
AU  - Najeeb S
AU  - Kaur V
AU  - Sukari A
AU  - Giri A
AU  - Panella TJ
AU  - Grewal J
AU  - Galligan B
AU  - Nadler E
AU  - Grant C
AU  - Arteta-Bulos R
AU  - Noble DJ
AU  - Schaaf D
AU  - Price KAR
PY  - 2026
JO  - JAMA oncology
DO  - 10.1001/jamaoncol.2026.3492
UR  - https://doi.org/10.1001/jamaoncol.2026.3492
ER  -

APA

J, W., J, K., A, C., FP, W., R, M., H, K., RG, Z., SM, A., P, B., K, H., S, G., Y, Z., DC, P., S, N., V, K., A, S., A, G., TJ, P., J, G., B, G., E, N., C, G., R, A., DJ, N., D, S., & KAR, P. (2026). PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.. JAMA oncology. https://doi.org/10.1001/jamaoncol.2026.3492

Source records

pubmed · retrieved 2026-09-25T17:23:49.788Z